Seattle Genetics (SGEN) 38.84 $SGEN
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
Business Wire - Wed Apr 16, 8:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
25.0% Return Seen to Date on SmarTrend Seattle Genetics Call (SGEN)
Comtex SmarTrend(R) - Mon Apr 14, 11:02AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 1 month, Seattle Genetics has returned 24.96% as of today's recent price of $37.70.
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS(R) (Brentuximab Vedotin) in Key Countries
Business Wire - Tue Apr 08, 8:01AM CDT
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab vedotin) in three key countries in Takeda's territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico. All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). In addition to these three countries, ADCETRIS is also commercially available in the U.S., European Union, Japan, Canada, Ukraine, Switzerland, Singapore, Norway, Liechtenstein and Iceland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including sALCL.
Downtrend Call Working As Seattle Genetics Stock Falls 18.2% (SGEN)
Comtex SmarTrend(R) - Mon Apr 07, 9:48AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 3 weeks, Seattle Genetics has returned 18.21% as of today's recent price of $41.09.
Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR
Business Wire - Mon Apr 07, 9:30AM CDT
---Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans-
5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Seattle Genetics Set to Possibly Rebound After Yesterday's Selloff of 4.78%
Comtex SmarTrend(R) - Thu Apr 03, 5:21PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $41.13 to a high of $44.60. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $43.76 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Seattle Genetics (SGEN) Showing Signs Of Being A Roof Leaker
at The Street - Thu Apr 03, 9:22AM CDT
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)
at The Street - Mon Mar 31, 11:03AM CDT
TheStreet's Jim Cramer notes that the "new pharma" stocks, such as Celgene (CELG) and Gilead (GILD), have pulled back significantly recently. Cramer notes that Celgene could earn $16 as early as 2017. He recommends the stock because it is selling for...
Is It Time to Buy These 2 Cancer-Fighting Companies?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 27, 4:42PM CDT
Investors shouldn't buy and sell shares on market whims and whispers. After all, markets can jump up and down when we least expect it, and that means the chances for predicting its direction over a short period of time is a coin flip, at best. ...
Will Vintafolide Approval Silence Endocyte Bears?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:38PM CDT
Unless you've been asleep for a week, you probably noticed that Endocyte shot up over 150% last Friday, before settling near a 100% gain. Nearly two years ago Merck made a deal with Endocyte potentially worth $1 billion. The uncommonly big deal...
Jim Cramer's Top Stock Picks: SBUX JWN Z SGEN
at The Street - Thu Mar 20, 5:00AM CDT
It may not seem obvious but Starbucks, Nordstrom, Zillow and Seattle Genetics are all technology companies, Cramer says, and that's why they will thrive.
Jim Cramer's 'Mad Money' Recap: Strong Economy, Everybody Wins
at The Street - Wed Mar 19, 7:11PM CDT
Time to pick among the rubble for beaten-down banks and other companies that will thrive as the U.S. economy finally recovers, Cramer says.
Cramer: Seductive Words of the Fisherman Skeptic
at The Street - Wed Mar 19, 9:00AM CDT
It's sardonic, corroded commentary designed to keep your pole in the boat.
Jim Cramer: This Froth Has to Be Reined In
at The Street - Mon Mar 17, 10:32AM CDT
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
Business Wire - Wed Apr 16, 8:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
25.0% Return Seen to Date on SmarTrend Seattle Genetics Call (SGEN)
Comtex SmarTrend(R) - Mon Apr 14, 11:02AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 1 month, Seattle Genetics has returned 24.96% as of today's recent price of $37.70.
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS(R) (Brentuximab Vedotin) in Key Countries
Business Wire - Tue Apr 08, 8:01AM CDT
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab vedotin) in three key countries in Takeda's territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico. All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). In addition to these three countries, ADCETRIS is also commercially available in the U.S., European Union, Japan, Canada, Ukraine, Switzerland, Singapore, Norway, Liechtenstein and Iceland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including sALCL.
Downtrend Call Working As Seattle Genetics Stock Falls 18.2% (SGEN)
Comtex SmarTrend(R) - Mon Apr 07, 9:48AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 3 weeks, Seattle Genetics has returned 18.21% as of today's recent price of $41.09.
Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR
Business Wire - Mon Apr 07, 9:30AM CDT
---Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans-
5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Seattle Genetics Set to Possibly Rebound After Yesterday's Selloff of 4.78%
Comtex SmarTrend(R) - Thu Apr 03, 5:21PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $41.13 to a high of $44.60. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $43.76 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Seattle Genetics (SGEN) Showing Signs Of Being A Roof Leaker
at The Street - Thu Apr 03, 9:22AM CDT
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)
at The Street - Mon Mar 31, 11:03AM CDT
TheStreet's Jim Cramer notes that the "new pharma" stocks, such as Celgene (CELG) and Gilead (GILD), have pulled back significantly recently. Cramer notes that Celgene could earn $16 as early as 2017. He recommends the stock because it is selling for...
Is It Time to Buy These 2 Cancer-Fighting Companies?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 27, 4:42PM CDT
Investors shouldn't buy and sell shares on market whims and whispers. After all, markets can jump up and down when we least expect it, and that means the chances for predicting its direction over a short period of time is a coin flip, at best. ...
Will Vintafolide Approval Silence Endocyte Bears?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:38PM CDT
Unless you've been asleep for a week, you probably noticed that Endocyte shot up over 150% last Friday, before settling near a 100% gain. Nearly two years ago Merck made a deal with Endocyte potentially worth $1 billion. The uncommonly big deal...
Jim Cramer's Top Stock Picks: SBUX JWN Z SGEN
at The Street - Thu Mar 20, 5:00AM CDT
It may not seem obvious but Starbucks, Nordstrom, Zillow and Seattle Genetics are all technology companies, Cramer says, and that's why they will thrive.
Jim Cramer's 'Mad Money' Recap: Strong Economy, Everybody Wins
at The Street - Wed Mar 19, 7:11PM CDT
Time to pick among the rubble for beaten-down banks and other companies that will thrive as the U.S. economy finally recovers, Cramer says.
Cramer: Seductive Words of the Fisherman Skeptic
at The Street - Wed Mar 19, 9:00AM CDT
It's sardonic, corroded commentary designed to keep your pole in the boat.
Jim Cramer: This Froth Has to Be Reined In
at The Street - Mon Mar 17, 10:32AM CDT
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
